Chugai Pharmaceutical Co. Ltd.

Chugai Pharmaceutical is a pharmaceutical company. Along with its subsidiaries, Co. is engaged in the research and development of new prescription medicines and the subsequent manufacturing, marketing and distribution activities. Co. sells its pharmaceutical products to the nationwide appointed stores in Japan, as well as in overseas, such as Germany, the U.K., France, Taiwan, China, South Korea and the U.S. Co., through its subsidiaries, is also involved in the management of research facilities, and the research on drug discovery, as well as the provision of literature research services for pharmaceutical information, and pharmaceutical academic information.
  • Ticker4519
  • ISINJP3519400000
  • SectorPharmaceuticals & Biotechnology
  • CountryJapan

Analysts

Jay Lee

Morningstar | Chugai Posts Strong Q1 Thanks to Sales of In-House Drugs, FVE Revised to JPY 6,500

Narrow-moat Chugai Pharmaceutical announced Q1 earnings that showed strong operating margins of 30%, an increase of 380 basis points year-over-year, or 200 basis points using Chugai’s core earnings. This was driven by increasing sales contribution from higher-margin in-house drugs, which improved gross margins. This is better than our expectations, and we believe it will be sustainable. As a result, we revised our fair value to JPY 6,500 per share from JPY 6,000 per share. Revenue this quarter grew 4.7% year-over-year, which is in line with our expectation. Gross profit margins (calculated as...

Jay Lee

Morningstar | Chugai Posts Strong Q1 Thanks to Sales of In-House Drugs, FVE Revised to JPY 6,500. See Updated Analyst Note from 26 Apr 2019

Narrow-moat Chugai Pharmaceutical announced Q1 earnings that showed strong operating margins of 30%, an increase of 380 basis points year-over-year, or 200 basis points using Chugai’s core earnings. This was driven by increasing sales contribution from higher-margin in-house drugs, which improved gross margins. This is better than our expectations, and we believe it will be sustainable. As a result, we revised our fair value to JPY 6,500 per share from JPY 6,000 per share. Revenue this quarter grew 4.7% year-over-year, which is in line with our expectation. Gross profit margins (calculated as...

Jay Lee

Chugai Posts Strong Q1 Thanks to Sales of In-House Drugs, FVE Revised to JPY 6,500

Narrow-moat Chugai Pharmaceutical announced Q1 earnings that showed strong operating margins of 30%, an increase of 380 basis points year-over-year, or 200 basis points using Chugai’s core earnings. This was driven by increasing sales contribution from higher-margin in-house drugs, which improved gross margins. This is better than our expectations, and we believe it will be sustainable. As a result, we revised our fair value to JPY 6,500 per share from JPY 6,000 per share. Revenue this quarter g...

Jay Lee

Morningstar | 4519 Updated Forecasts and Estimates from 11 Feb 2019

Chugai Pharmaceutical announced 2018 earnings that were in line with our expectations. We are transferring coverage to a new analyst and raising our fair value estimate to JPY 6,000 per share from 4,820. This is primarily due to an update to Morningstar’s cost of equity assumption for Japanese stocks. We maintain our narrow moat and stable moat trend ratings. The earnings metrics were broadly in line with our expectations. Revenue growth was 8.5% versus our estimate of 7.6%, primarily due to higher royalties and other income in the fourth quarter. Operating margins for the full year were 21.4...

Jay Lee

Morningstar | Chugai's 2018 Earnings Strong as Expected; Raising FVE to JPY 6,000 on Change in WACC

Chugai Pharmaceutical announced 2018 earnings that were in line with our expectations. We are transferring coverage to a new analyst and raising our fair value estimate to JPY 6,000 per share from 4,820. This is primarily due to an update to Morningstar’s cost of equity assumption for Japanese stocks. We maintain our narrow moat and stable moat trend ratings. The earnings metrics were broadly in line with our expectations. Revenue growth was 8.5% versus our estimate of 7.6%, primarily due to higher royalties and other income in the fourth quarter. Operating margins for the full year were 21.4...

Jay Lee

Morningstar | Chugai Posts Strong Q1 Thanks to Sales of In-House Drugs, FVE Revised to JPY 6,500

Narrow-moat Chugai Pharmaceutical announced Q1 earnings that showed strong operating margins of 30%, an increase of 380 basis points year-over-year, or 200 basis points using Chugai’s core earnings. This was driven by increasing sales contribution from higher-margin in-house drugs, which improved gross margins. This is better than our expectations, and we believe it will be sustainable. As a result, we revised our fair value to JPY 6,500 per share from JPY 6,000 per share. Revenue this quarter grew 4.7% year-over-year, which is in line with our expectation. Gross profit margins (calculated as...

Jay Lee

Morningstar | Chugai Posts Strong Q1 Thanks to Sales of In-House Drugs, FVE Revised to JPY 6,500. See Updated Analyst Note from 26 Apr 2019

Narrow-moat Chugai Pharmaceutical announced Q1 earnings that showed strong operating margins of 30%, an increase of 380 basis points year-over-year, or 200 basis points using Chugai’s core earnings. This was driven by increasing sales contribution from higher-margin in-house drugs, which improved gross margins. This is better than our expectations, and we believe it will be sustainable. As a result, we revised our fair value to JPY 6,500 per share from JPY 6,000 per share. Revenue this quarter grew 4.7% year-over-year, which is in line with our expectation. Gross profit margins (calculated as...

Jay Lee

Chugai Posts Strong Q1 Thanks to Sales of In-House Drugs, FVE Revised to JPY 6,500

Narrow-moat Chugai Pharmaceutical announced Q1 earnings that showed strong operating margins of 30%, an increase of 380 basis points year-over-year, or 200 basis points using Chugai’s core earnings. This was driven by increasing sales contribution from higher-margin in-house drugs, which improved gross margins. This is better than our expectations, and we believe it will be sustainable. As a result, we revised our fair value to JPY 6,500 per share from JPY 6,000 per share. Revenue this quarter g...

Jay Lee

Morningstar | 4519 Updated Forecasts and Estimates from 11 Feb 2019

Chugai Pharmaceutical announced 2018 earnings that were in line with our expectations. We are transferring coverage to a new analyst and raising our fair value estimate to JPY 6,000 per share from 4,820. This is primarily due to an update to Morningstar’s cost of equity assumption for Japanese stocks. We maintain our narrow moat and stable moat trend ratings. The earnings metrics were broadly in line with our expectations. Revenue growth was 8.5% versus our estimate of 7.6%, primarily due to higher royalties and other income in the fourth quarter. Operating margins for the full year were 21.4...

Jay Lee

Morningstar | Chugai's 2018 Earnings Strong as Expected; Raising FVE to JPY 6,000 on Change in WACC

Chugai Pharmaceutical announced 2018 earnings that were in line with our expectations. We are transferring coverage to a new analyst and raising our fair value estimate to JPY 6,000 per share from 4,820. This is primarily due to an update to Morningstar’s cost of equity assumption for Japanese stocks. We maintain our narrow moat and stable moat trend ratings. The earnings metrics were broadly in line with our expectations. Revenue growth was 8.5% versus our estimate of 7.6%, primarily due to higher royalties and other income in the fourth quarter. Operating margins for the full year were 21.4...

Joel Scheiman ...
  • Julie Boote
  • Thao Nguyen

PSA Today Mar 2: US steel tariff proposals, stronger yen damage markets/ Blast furnace shares fall, arc up/Auto sector under pressure/Kakaku's successful tabelog sign-ups - Nikkei -2.50%

Japan Market Comment by Julie Boote, Joel Scheiman and Thao Nguyen Nikkei ¥21,181.64 (-¥542.83 / -2.50%); Topix ¥1,708.34 (-¥31.86 / -1.83%); ¥/$105.85 Tags: Nippon Steel & Sumitomo Metal Corp (5401 JP), JFE Holdings (5411 JP), Kobe Steel (5406 JP), Nisshin Steel (5413 JP), Yamato Kogyo (5444 JP), Olympus (7733 JP), Hoya (7741 JP), Chugai Pharma (4519 JP), Tokai Carbon (5301 JP), Sumco (3436 JP), Isuzu Motors (7202 JP), Toyota (7203 JP), Honda (7267 JP), Subaru (7270 JP), Nissan (7201 JP), Kakaku.com (2371 JP), Main Points at a Glance • Wall Street declines, US policy and a stronger yen aff...

CHUGAI PHARM.CO.LTD. sees a downgrade to Slightly Negative on account of less fundamental stars

The independent financial analyst theScreener just lowered the general evaluation of CHUGAI PHARM.CO.LTD. (JP), active in the Pharmaceuticals industry. As regards its fundamental valuation, the title now shows 1 out of 4 stars while market behaviour can be considered moderately risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Slightly Negative. As of the analysis date January 15, 2019, the closing price was JPY 6,540.00 and its target price was estimated at JPY 5,858.32.

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

MarketLine Department

Takeda Pharmaceutical Company Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's Takeda Pharmaceutical Company Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Takeda Pharmaceutical Company Limited since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Int'l Compass: Global Equity Strategy

Bottoms-up view on developed int'l, part two Big Picture: Our outlook remains neutral on the MSCI ACWI ex-U.S. index (when priced in local currency) while horizontal consolidation continues. On the other hand, we are negative on broad global ex-U.S. markets when priced in USD... see charts below. In today's report we take a bottoms-up approach to developed ex-U.S. equities, highlighting stocks that present attractive buy opportunities at current levels. Specifically we present actionable stocks within the Communications, Health Care, Manufacturing, Materials, Technology, Transportation, and U...

Dave Nicoski ...
  • Ross LaDuke

Int'l Macro Vision: Global Equity Strategy

Investors have endured turbulent year-to-date price action as volatility has been re-introduced to global markets. Owing to various concerns ranging from rising interest rates to an all-out trade war, most major indexes are testing critical support levels. In addition, market internals have begun to paint a mixed picture. Given the current state of the market, what do technicals suggest is next for global equities? In the short-term we believe the most likely scenario is a continuation of the recent consolidation and heightened volatility across global markets. While support levels have held...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch